ANDA 40078, held by Hospira. Lidocaine Hydrochloride.
As of Nov 16, 2026, ANDA 40078 (Lidocaine Hydrochloride), held by Hospira, was first approved by FDA on Jun 23, 1995, with 9 approved supplements and 0 published complete response letters.
INDICATIONS AND USAGE Lidocaine HCl injection is indicated for production of local or regional anesthesia by infiltration techniques such as percutaneous injection and by peripheral nerve block techniques such as brachial plexus and intercostal and by central neural techniques such as lumbar and caudal epidural blocks, when the accepted procedures for these techniques as described in standard textbooks are observed.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Jun 23, 1995 | Original application | Approved | None posted |
| Product | Active ingredient | Marketing |
|---|---|---|
| Lidocaine Hydrochloride2% · injectable;injection | Lidocaine Hydrochloride | Rx |
| Jun 5, 2026 | Supplement 38Labeling · Standard review | Approved | None posted |
| Feb 28, 2020 | Supplement 24Labeling · Standard review | Approved | None posted |
| Feb 28, 2020 | Supplement 22Labeling · Standard review | Approved | None posted |
| Apr 16, 2010 | Supplement 13Labeling | Approved | None posted |
| Nov 4, 2009 | Supplement 12Labeling | Approved | None posted |
| Jan 2, 2002 | Supplement 4Labeling | Approved | None posted |
| Feb 14, 2001 | Supplement 3Manufacturing | Approved | None posted |
| May 24, 1996 | Supplement 2Manufacturing | Approved | None posted |
| Dec 1, 1995 | Supplement 1Manufacturing | Approved | None posted |
| Jun 23, 1995 | Original application | Approved | None posted |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters